To test this hypothesis, we first examined the effect of GSKJ4, a specific JMJD3 inhibitor, on the development of renal fibrosis in the same UUO model used for uncovering the anti-fibrotic effect of EZH2 inhibition 14. This evidence concerns the gene KDM6B and renal fibrosis.